{"title":"PN - HPT治疗术后萎缩凹陷疤痕的探索性研究。","authors":"Antonino Araco, Francesco Araco, Mauro Raichi","doi":"10.1111/jocd.16764","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Postsurgical atrophic scars tend to respond poorly to treatments, especially non-energy-based ones. Hydrophilic PN HPT (Polynucleotides High Purification Technology) injected intradermally is a non-energy-based option with an immediate volume-enhancing effect that indirectly improves the fibroblast synthesis of collagen and extracellular matrix. The PN HPT ingredient has the further benefit of a dermal “priming” effect that enhances the efficacy of other scar treatments.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Verify retrospectively, with advanced techniques, the efficacy of PN HPT monotherapy as postsurgical scar treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Retrospective data collection in 18- to 65-year-old women with moderate-to-severe atrophic scars after mammary surgery undergoing a five-session intradermal treatment course with 0.75% PN HPT gel formulation in single-use syringes starting 6 months after surgery. Primary retrospective efficacy parameter: changes in scar morphology and symptom severity after three and 6 months (modified Vancouver Scar Scale, mVSS). Secondary efficacy parameters: roughness score 6 months after baseline (Antera 3D CS tridimensional skin analysis system) and Global Aesthetic Improvement Scale (GAIS, Investigator and Patient subscales) after three and 6 months.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Total mean mVSS highly significantly improved from 11.2 ± 1.92 at baseline to 7.0 ± 1.68 and 6.9 ± 1.55 after three and 6 months, respectively; the mean Antera 3D CS roughness score improved from 13.5 ± 4.14 to 10.0 ± 3.49 after 6 months. After three and 6 months, the GAIS subscores for investigators and cohort subjects were identical (3.0 ± 0.81 and 3.0 ± 0.72, respectively). The photographic documentation supported the previous results.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In monotherapy, the intradermal PN HPT ingredient seems to quickly and safely relieve the burden of postsurgical atrophic scars. However, the lack of a formal parallel control group is a severe limitation. The objective quantitative measurements confirmed the long-lasting benefits.</p>\n </section>\n </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"24 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734378/pdf/","citationCount":"0","resultStr":"{\"title\":\"An Exploratory Study of PN HPT for Treating Postsurgical Atrophic and Depressed Scars\",\"authors\":\"Antonino Araco, Francesco Araco, Mauro Raichi\",\"doi\":\"10.1111/jocd.16764\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Postsurgical atrophic scars tend to respond poorly to treatments, especially non-energy-based ones. Hydrophilic PN HPT (Polynucleotides High Purification Technology) injected intradermally is a non-energy-based option with an immediate volume-enhancing effect that indirectly improves the fibroblast synthesis of collagen and extracellular matrix. The PN HPT ingredient has the further benefit of a dermal “priming” effect that enhances the efficacy of other scar treatments.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Verify retrospectively, with advanced techniques, the efficacy of PN HPT monotherapy as postsurgical scar treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Retrospective data collection in 18- to 65-year-old women with moderate-to-severe atrophic scars after mammary surgery undergoing a five-session intradermal treatment course with 0.75% PN HPT gel formulation in single-use syringes starting 6 months after surgery. Primary retrospective efficacy parameter: changes in scar morphology and symptom severity after three and 6 months (modified Vancouver Scar Scale, mVSS). Secondary efficacy parameters: roughness score 6 months after baseline (Antera 3D CS tridimensional skin analysis system) and Global Aesthetic Improvement Scale (GAIS, Investigator and Patient subscales) after three and 6 months.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Total mean mVSS highly significantly improved from 11.2 ± 1.92 at baseline to 7.0 ± 1.68 and 6.9 ± 1.55 after three and 6 months, respectively; the mean Antera 3D CS roughness score improved from 13.5 ± 4.14 to 10.0 ± 3.49 after 6 months. After three and 6 months, the GAIS subscores for investigators and cohort subjects were identical (3.0 ± 0.81 and 3.0 ± 0.72, respectively). The photographic documentation supported the previous results.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>In monotherapy, the intradermal PN HPT ingredient seems to quickly and safely relieve the burden of postsurgical atrophic scars. However, the lack of a formal parallel control group is a severe limitation. The objective quantitative measurements confirmed the long-lasting benefits.</p>\\n </section>\\n </div>\",\"PeriodicalId\":15546,\"journal\":{\"name\":\"Journal of Cosmetic Dermatology\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734378/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cosmetic Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jocd.16764\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cosmetic Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jocd.16764","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：手术后萎缩性疤痕往往对治疗反应不佳，特别是非能量基础的治疗。皮内注射的亲水性PN HPT（多核苷酸高纯化技术）是一种非能量基础的选择，具有立即的体积增强效果，间接改善胶原蛋白和细胞外基质的成纤维细胞合成。PN HPT成分具有进一步的真皮“启动”效果，增强其他疤痕治疗的功效。目的：回顾性验证先进技术下PN - HPT单药治疗术后瘢痕的疗效。方法：回顾性收集18 ~ 65岁乳房手术后出现中重度萎缩性疤痕的女性患者的资料，从术后6个月开始，用一次性注射器给予0.75% PN HPT凝胶配方皮内治疗。主要回顾性疗效参数：3个月和6个月后疤痕形态和症状严重程度的变化（改良温哥华疤痕量表，mVSS）。次要疗效参数：基线后6个月的粗糙度评分（Antera 3D CS三维皮肤分析系统）和3个月和6个月后的全球美学改善量表（GAIS，研究者和患者亚量表）。结果：3个月和6个月后，总平均mVSS分别从基线时的11.2±1.92提高到7.0±1.68和6.9±1.55；6个月后，平均Antera 3D CS粗糙评分由13.5±4.14分提高到10.0±3.49分。3个月和6个月后，研究者和队列受试者的GAIS评分相同（分别为3.0±0.81和3.0±0.72）。摄影文献支持了先前的结果。结论：在单药治疗中，皮内PN - HPT成分似乎可以快速安全地减轻术后萎缩性疤痕的负担。然而，缺乏一个正式的平行对照组是一个严重的限制。客观的定量测量证实了长期的益处。
An Exploratory Study of PN HPT for Treating Postsurgical Atrophic and Depressed Scars
Background
Postsurgical atrophic scars tend to respond poorly to treatments, especially non-energy-based ones. Hydrophilic PN HPT (Polynucleotides High Purification Technology) injected intradermally is a non-energy-based option with an immediate volume-enhancing effect that indirectly improves the fibroblast synthesis of collagen and extracellular matrix. The PN HPT ingredient has the further benefit of a dermal “priming” effect that enhances the efficacy of other scar treatments.
Objectives
Verify retrospectively, with advanced techniques, the efficacy of PN HPT monotherapy as postsurgical scar treatment.
Methods
Retrospective data collection in 18- to 65-year-old women with moderate-to-severe atrophic scars after mammary surgery undergoing a five-session intradermal treatment course with 0.75% PN HPT gel formulation in single-use syringes starting 6 months after surgery. Primary retrospective efficacy parameter: changes in scar morphology and symptom severity after three and 6 months (modified Vancouver Scar Scale, mVSS). Secondary efficacy parameters: roughness score 6 months after baseline (Antera 3D CS tridimensional skin analysis system) and Global Aesthetic Improvement Scale (GAIS, Investigator and Patient subscales) after three and 6 months.
Results
Total mean mVSS highly significantly improved from 11.2 ± 1.92 at baseline to 7.0 ± 1.68 and 6.9 ± 1.55 after three and 6 months, respectively; the mean Antera 3D CS roughness score improved from 13.5 ± 4.14 to 10.0 ± 3.49 after 6 months. After three and 6 months, the GAIS subscores for investigators and cohort subjects were identical (3.0 ± 0.81 and 3.0 ± 0.72, respectively). The photographic documentation supported the previous results.
Conclusions
In monotherapy, the intradermal PN HPT ingredient seems to quickly and safely relieve the burden of postsurgical atrophic scars. However, the lack of a formal parallel control group is a severe limitation. The objective quantitative measurements confirmed the long-lasting benefits.
期刊介绍：
The Journal of Cosmetic Dermatology publishes high quality, peer-reviewed articles on all aspects of cosmetic dermatology with the aim to foster the highest standards of patient care in cosmetic dermatology. Published quarterly, the Journal of Cosmetic Dermatology facilitates continuing professional development and provides a forum for the exchange of scientific research and innovative techniques.
The scope of coverage includes, but will not be limited to: healthy skin; skin maintenance; ageing skin; photodamage and photoprotection; rejuvenation; biochemistry, endocrinology and neuroimmunology of healthy skin; imaging; skin measurement; quality of life; skin types; sensitive skin; rosacea and acne; sebum; sweat; fat; phlebology; hair conservation, restoration and removal; nails and nail surgery; pigment; psychological and medicolegal issues; retinoids; cosmetic chemistry; dermopharmacy; cosmeceuticals; toiletries; striae; cellulite; cosmetic dermatological surgery; blepharoplasty; liposuction; surgical complications; botulinum; fillers, peels and dermabrasion; local and tumescent anaesthesia; electrosurgery; lasers, including laser physics, laser research and safety, vascular lasers, pigment lasers, hair removal lasers, tattoo removal lasers, resurfacing lasers, dermal remodelling lasers and laser complications.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
